UNITED THERAPEUTICS Corp 4

EVP & General Counsel Paul A. Mahon exercised 8,300 United Therapeutics stock options at $146.03 and sold the resulting 8,300 shares around $528–$537 per share on July 16, 2026 under a 10b5-1 plan.

On July 16, 2026, United Therapeutics Corporation EVP & General Counsel Paul A. Mahon exercised 8,300 stock options with a strike price of $146.03 per share, acquiring 8,300 shares of common stock, and on the same date sold those 8,300 shares in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan. The option exercise increased his directly held common stock to 53,472 shares at the time of acquisition, after which he disposed of 8,300 shares in multiple sales priced between approximately $527.60 and $536.85 per share, generating total sale proceeds of roughly $4.4–$4.5 million and yielding an intrinsic gain of about $3.2–$3.3 million relative to the $146.03 exercise price. Following these transactions, Mahon reported direct ownership of 45,172 shares of United Therapeutics common stock; using the prevailing sale prices as a proxy (around $535 per share), his remaining equity stake is worth on the order of $24 million. The filing characterizes the activity as a routine option exercise and related sale for liquidity under a 10b5-1 plan rather than an open-ended discretionary sale of long-held shares.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001231589-26-000016

Alert Tier

6